27 August 2018 : Clinical Research
MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2)
Na Li1BC, Mei Han1AB, Ning Zhou1BC, Yong Tang1DE, Xu-Shan Tang1DE*DOI: 10.12659/MSM.909458
Med Sci Monit 2018; 24: CLR5960-5972
Abstract
BACKGROUND: In recent years, the incidence of gastric cancer (GC) presents is increasing and plagues people worldwide. Emerging evidence shows that microRNAs (miRs) may be involved in the pathogenesis of GC. Thus, this paper aims to explore the mediatory role of miR-495 in GC chemosensitivity, and the mechanism by which it affected the biological behaviors of GC cell via the mTOR signaling pathway.
MATERIAL AND METHODS: After GC and paracancerous tissue collection, the positive rate of ERBB2 and mTOR was evaluated by immunohistochemistry. Subsequently, the expression of miR-495, ERBB2 and mTOR was determined by RT-qPCR and western blot analysis. Next, the targeting relationship between miR-495 and ERBB2 was confirmed by dual-luciferase reporter gene assay. In addition, chemosensitivity and proliferation were detected by MTT assay, and apoptosis by flow cytometry.
RESULTS: We firstly observed that higher positive rate of ERBB2 and mTOR as well as decreased expression of miR-495 were found in GC tissues. Additionally, ERBB2 is the target gene of miR-495. Furthermore, it was determined that overexpressed miR-495 or silencing ERBB2 enhanced GC cells chemosensitivity and apoptosis, but inhibited GC cell proliferation. Besides, we found that the effect of miR-495 inhibition was lost when ERBB2 was suppressed.
CONCLUSIONS: The key findings of our study demonstrate that the miR-495 exerts promoting effects on GC chemosensitivity via the inactivation of mTOR signaling pathway by suppressing ERBB2. The study provides reliable reference for the application of miR-495 as a novel potential target in the chemotherapy of GC.
Keywords: Gastroenterology, Stomach Diseases
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952